Showing 5951-5960 of 10225 results for "".
- Sun Pharma to Acquire Concert Pharmaceuticals, Maker of Alopecia Areata Treatment Candidatehttps://practicaldermatology.com/news/sun-pharma-to-acquire-concert-pharmaceuticals-maker-of-alopecia-areata-treatment-candidate/2461519/Sun Pharmaceutical Industries announced it has acquired Concert Pharmaceuticals for about $576 million in equity value, according to a company news release. Concert’s lead product candidate is deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia a
- University of Missouri-Columbia-Developed Teledermatology Program Improves Diagnosis of Skin Conditions in Underserved Communitieshttps://practicaldermatology.com/news/university-of-missouri-columbia-developed-teledermatology-program-improves-diagnosis-of-skin-conditions-in-underserved-communities/2461517/A teledermatology program first developed by the University of Missouri in 2015 can help improve the diagnoses of skin conditions in underserved communities, according to a new study in Journal of Telemedicine
- Elsevier Introduces First 3D Human Anatomy Model in Different Skin Toneshttps://practicaldermatology.com/news/elsevier-introduces-first-3d-human-anatomy-model-in-different-skin-tones/2461516/Elsevier is rolling out the newest edition of its 3D anatomy teaching platform, Complete Anatomy 2023, which will feature the most expansive set of skin tone selections ever available in global health education.
- Phase 2b Study: Arcutis' Roflumilast Cream Shows Sustained Efficacy in Adults with Chronic Plaque Psoriasishttps://practicaldermatology.com/news/pgase-2b-study-arcutis-roflumilast-cream-shows-sustained-efficacy-in-adults-with-chronic-plaque-psoriasis/2461513/Arcutis' roflumilast cream showed sustained efficacy with clearance for median of 10 Months in adults with chronic plaque psoriasis, according to an open label Phase 2 long-term safety study presented at the Winter Clinical dermatology meeting. Roflumilast cream
- La Roche Posay Celebrates Second Annual National HA Day on Jan. 21, 2023https://practicaldermatology.com/news/la-roche-posay-celebrates-second-annual-national-ha-day-on-jan-21-2023/2461510/La Roche-Posay is ringing in its second annual National Hyaluronic Acid Day on January 21st. To celebrate National Hyaluronic Acid Day, the brand is offering 20% off on orders of $65 or more on
- Simple Laser Treatments May Help Prevent Nonmelanoma Skin Cancerhttps://practicaldermatology.com/news/simple-laser-treatments-may-help-prevent-nonmelanoma-skin-cancer/2461508/Nonablative fractional lasers treatments may help prevent basal cell carcinoma and squamous cell carcinoma, a new study suggests. Nonablative fractional lasers (NAFL) are currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for pre
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Launch Digital Online Free Image Galleryhttps://practicaldermatology.com/news/the-full-spectrum-of-dermatology-a-diverse-and-inclusive-atlas-launch-digital-online-free-image-gallery/2461500/“The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas” is launching a digital online free image gallery. The
- Algae May Enhance Skin Regeneration and Wound Healing: Studyhttps://practicaldermatology.com/news/algae-may-enhance-skin-regeneration-and-wound-healing-study/2461496/Euglena gracilis may enhance skin regeneration to speed wound healing, according to new research. Investigators developed a system based on microvesicles that bud from the cell surface of Euglena gracilis, a freshwater single-celled green algae, and conta
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no